BRPI0411820B8 - composição farmacêutica para administração parenteral, e seus usos - Google Patents

composição farmacêutica para administração parenteral, e seus usos

Info

Publication number
BRPI0411820B8
BRPI0411820B8 BRPI0411820A BRPI0411820A BRPI0411820B8 BR PI0411820 B8 BRPI0411820 B8 BR PI0411820B8 BR PI0411820 A BRPI0411820 A BR PI0411820A BR PI0411820 A BRPI0411820 A BR PI0411820A BR PI0411820 B8 BRPI0411820 B8 BR PI0411820B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
parenteral administration
somatostatin
parenteral
relates
Prior art date
Application number
BRPI0411820A
Other languages
English (en)
Inventor
Moser Katrin
Lambert Olivier
Original Assignee
Novartis Ag
Recordati Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33554159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411820(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0314695A external-priority patent/GB0314695D0/en
Priority claimed from GB0325388A external-priority patent/GB0325388D0/en
Application filed by Novartis Ag, Recordati Ag filed Critical Novartis Ag
Publication of BRPI0411820A publication Critical patent/BRPI0411820A/pt
Publication of BRPI0411820B1 publication Critical patent/BRPI0411820B1/pt
Publication of BRPI0411820B8 publication Critical patent/BRPI0411820B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form

Abstract

composição farmacêutica. a presente invenção refere-se a composições farmacêuticas parenterais compreendendo um análogo de somatostatina e novos análogos de somatostatina.
BRPI0411820A 2003-06-24 2004-06-23 composição farmacêutica para administração parenteral, e seus usos BRPI0411820B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0314695A GB0314695D0 (en) 2003-06-24 2003-06-24 Organic compounds
GB0314695.8 2003-06-24
GB0325388A GB0325388D0 (en) 2003-10-30 2003-10-30 Organic compounds
GB0325388.7 2003-10-30
PCT/EP2004/006794 WO2005000893A2 (en) 2003-06-24 2004-06-23 Pharmaceutical composition comprising cyclic somatostin analogues

Publications (3)

Publication Number Publication Date
BRPI0411820A BRPI0411820A (pt) 2006-08-08
BRPI0411820B1 BRPI0411820B1 (pt) 2019-06-25
BRPI0411820B8 true BRPI0411820B8 (pt) 2021-05-25

Family

ID=33554159

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411820A BRPI0411820B8 (pt) 2003-06-24 2004-06-23 composição farmacêutica para administração parenteral, e seus usos

Country Status (32)

Country Link
US (3) US20070093412A1 (pt)
EP (1) EP1648934B1 (pt)
JP (1) JP4746541B2 (pt)
KR (1) KR101124136B1 (pt)
AR (1) AR044852A1 (pt)
AT (1) ATE438659T1 (pt)
AU (1) AU2004251866B2 (pt)
BR (1) BRPI0411820B8 (pt)
CA (1) CA2529449C (pt)
CL (1) CL2004001579A1 (pt)
CO (1) CO5650225A2 (pt)
CY (1) CY1109444T1 (pt)
DE (1) DE602004022420D1 (pt)
DK (1) DK1648934T3 (pt)
EC (1) ECSP056237A (pt)
ES (1) ES2328144T3 (pt)
HK (1) HK1089776A1 (pt)
HR (1) HRP20090571T1 (pt)
IL (1) IL172329A (pt)
IS (1) IS2705B (pt)
MA (1) MA27862A1 (pt)
MX (1) MXPA05013821A (pt)
MY (1) MY145375A (pt)
NO (1) NO330706B1 (pt)
NZ (1) NZ544157A (pt)
PE (1) PE20050285A1 (pt)
PL (1) PL1648934T3 (pt)
PT (1) PT1648934E (pt)
RU (1) RU2355418C2 (pt)
SI (1) SI1648934T1 (pt)
TW (1) TWI361194B (pt)
WO (1) WO2005000893A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008329826B2 (en) 2007-11-28 2013-01-17 Novartis Ag Use of somatostatin analogs in meningioma
SI2225271T1 (sl) * 2007-12-03 2013-10-30 Italfarmaco S.P.A. Novi selektivni analogi somatostatina
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
TWI633887B (zh) 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
HUE043374T2 (hu) * 2013-09-30 2019-08-28 Ono Pharmaceutical Co Vegyület, amelynek van szomatosztatin receptor agonista aktivitása és annak gyógyszerészeti felhasználása
CN104447962B (zh) * 2014-12-29 2018-07-17 成都圣诺生物科技股份有限公司 一种合成帕瑞肽的方法
GB201816637D0 (en) 2018-10-12 2018-11-28 Heptares Therapeutics Ltd Selective somatostatin receptor agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328214A (en) * 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
DE3264693D1 (en) * 1981-12-24 1985-08-14 Ciba Geigy Ag Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use
US4612366A (en) * 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
JPH02111A (ja) * 1987-08-03 1990-01-05 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド製剤
US5059587A (en) 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
JP2641755B2 (ja) 1988-01-29 1997-08-20 住友製薬株式会社 コントロールリリース製剤
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
DE69426673T2 (de) 1993-06-23 2001-09-20 Diatide Inc Radiomarkierte somatostatin derivate zur abbildung und zur therapeutischen verwendung
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
ES2167189B1 (es) 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP2310042B1 (en) * 2008-07-08 2012-12-05 Novartis AG Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia

Also Published As

Publication number Publication date
AU2004251866B2 (en) 2008-06-12
BRPI0411820A (pt) 2006-08-08
SI1648934T1 (sl) 2010-01-29
TW200514789A (en) 2005-05-01
RU2355418C2 (ru) 2009-05-20
KR101124136B1 (ko) 2012-03-21
CY1109444T1 (el) 2014-08-13
RU2006101720A (ru) 2007-08-10
CO5650225A2 (es) 2006-06-30
PL1648934T3 (pl) 2010-01-29
AU2004251866A1 (en) 2005-01-06
PT1648934E (pt) 2009-10-23
WO2005000893A2 (en) 2005-01-06
HK1089776A1 (en) 2006-12-08
CA2529449C (en) 2012-05-15
KR20060030052A (ko) 2006-04-07
CL2004001579A1 (es) 2005-05-20
MA27862A1 (fr) 2006-04-03
ATE438659T1 (de) 2009-08-15
NZ544157A (en) 2008-07-31
WO2005000893A3 (en) 2005-04-07
IL172329A0 (en) 2009-02-11
DK1648934T3 (da) 2009-10-26
MXPA05013821A (es) 2006-02-28
NO20060375L (no) 2006-01-24
DE602004022420D1 (de) 2009-09-17
US20090137462A1 (en) 2009-05-28
HRP20090571T1 (en) 2009-11-30
TWI361194B (en) 2012-04-01
AR044852A1 (es) 2005-10-05
NO330706B1 (no) 2011-06-20
IS8247A (is) 2006-01-20
US20070093412A1 (en) 2007-04-26
PE20050285A1 (es) 2005-06-09
CA2529449A1 (en) 2005-01-06
JP4746541B2 (ja) 2011-08-10
US20130035286A1 (en) 2013-02-07
IS2705B (is) 2010-12-15
IL172329A (en) 2013-12-31
EP1648934A2 (en) 2006-04-26
US8299209B2 (en) 2012-10-30
JP2007536195A (ja) 2007-12-13
MY145375A (en) 2012-01-31
BRPI0411820B1 (pt) 2019-06-25
ECSP056237A (es) 2006-04-19
EP1648934B1 (en) 2009-08-05
ES2328144T3 (es) 2009-11-10

Similar Documents

Publication Publication Date Title
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
BRPI0411528A (pt) uso de isomalte como prebiótico
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
UA86622C2 (ru) Фармацевтическая композиция, которая диспергируется в ротовой полости, для введения в слизистую оболочку ротовой полости или подъязычного введения агомелатина
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
EP1708719A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITIONS OF 2,6-DIISOPROPYLPHENOL (PROPOFOL) AND THEIR USE
BRPI0411316A (pt) uso de uma toxina clostrìdica para reduzir o apetite
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
NO20063393L (no) Farmasoytiske preparater
BRPI0620229A8 (pt) formulação
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
NO20064808L (no) Orale matrixformuleringer med licarbazepin
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
BRPI0408895A (pt) formulações de cladribina para administração oral e transmucosal aperfeiçoada
UY31103A1 (es) Composiciones farmaceuticas en base a microparticulas comprendiendo un analogo de somatostatina, proceso de preparacion y aplicaciones
ECSP056237A (es) Composición farmacéutica que comprende análogos de somatostatina cíclicos
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
TNSN05310A1 (en) Pharmaceutical composition comprising cyclic somatostatin analogues
UY27628A1 (es) "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco"
BRPI0408209A (pt) novas composições
NO20085189L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamid-benzotaizepiner, fremstilling og anvendelse derav sammensetninger inneholdende samme
DK1604683T3 (da) Gangliogsid-baserede vaccinesammensætninger til subkutan administration

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: RECORDATI AG (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF